Skip to main content
  • Advertise
    Want to Advertise with Us?
    Conquer welcomes advertising and sponsorship collaborations with reputable companies offering high-quality products and services to people affected by cancer.
  • Affiliated Brands
    Academy of Oncology Nurse & Patient Navigators
    The Academy of Oncology Nurse & Patient Navigators (AONN+) is the largest national specialty organization dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators. Our organization of over 8,900 members was founded in May 2009 to provide a network for all professionals involved and interested in patient navigation and survivorship care services to better manage the complexities of the cancer care treatment continuum for their patients. We view our organization as one consisting of “professional patient advocates” and, to that end, we support and serve our members.
    Journal of Oncology Navigation & Survivorship
    The Journal of Oncology Navigation & Survivorship (JONS) promotes reliance on evidence-based practices in navigating patients with cancer and their caregivers through diagnosis, treatment, and survivorship. JONS also seeks to strengthen the role of nurse and patient navigators in cancer care by serving as a platform for these professionals to disseminate original research findings, exchange best practices, and find support for their growing community.
    The Oncology Nurse-APN/PA
    The Oncology Nurse-APN/PA (TON) provides coverage of the wide spectrum of oncology-related events, trends, news, therapeutics, diagnostics, organizations, and legislation that directly affect hematology/oncology nurses and advanced practitioners involved in healthcare delivery and product utilization. The scope and coverage include a unique presentation of news and events that are shaping the care of patients with cancer.
  • Healthcare Providers
  • Contribute

November 2020 – Lung Cancer

Lung Cancer Stigma Can Cause Death
In her introduction to the November 2020 issue that is focused on lung cancer, Lillie D. Shockney discusses the articles and dispels the common assumption that only smokers get lung cancer. Read More ›

Just Ask Frank Sierawski: Anybody with Lungs Can Get Lung Cancer
Frank Sierawski had never smoked and had no family or personal history of lung problems, but what started out as a distressing cough ended up being lung cancer. Read More ›

Nutrition Tips for Patients with Lung Cancer: Maintaining a Healthy Body Weight
Oncology nutritionist Julie Lanford presents nutrition tips for patients with lung cancer, advocating for a health plan to combat unintentional weight loss and managing poor appetite. Read More ›

Why I Fight for Lung Cancer Awareness
When her mother was diagnosed with stage IIIB lung cancer, Danielle Hicks took an active role in caring for her and found her purpose helping other patients going through the same fight. Read More ›

Gavreto Second Drug FDA Approved for Patients with Metastatic Lung Cancer and RET Fusions
In September 2020, the FDA approved a second drug for the treatment of patients with lung cancer and RET fusions, improving the treatment options available today for patients with this type of lung cancer. Read More ›

Beauty Is a Side Effect of (Lung) Cancer
A.J. Patel, who ran around 20 miles a week as a semi-professional soccer referee, was shocked to get a lung cancer diagnosis and dismayed when his relationships strained. Then, an estranged uncle came to his aid. Read More ›

A Walk on Nature’s Path
Pattie Dorf created a painting of two people walking through the woods that expresses her feeling that “our life can create the choices we make with illness.” Read More ›

New Therapies Improve Survival in Patients with Lung Cancer Associated with a Biomarker
At the October 2020 conference of the European Society for Medical Oncology (ESMO), researchers presented information on new or recently approved targeted therapies and immunotherapies for lung cancer. Read More ›

Retevmo First Drug FDA Approved for Patients with Metastatic Lung Cancer and RET Fusions
In May 2020, the FDA approved the first drug ever for the treatment of patients with lung cancer and RET fusions, a type of biomarker that can lead to lung cancer and requires specific drug therapy. Read More ›

Oncogene Alterations Affect the Response to Targeted Therapies in Patients with Non–Small-Cell Lung Cancer and ALK Rearrangements
One biomarker that is involved in lung cancer is the ALK mutations. Although several drugs are now available for this type of lung cancer, new evidence shows that some patients may need different therapies. Read More ›